Natera, Inc.(NTRA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NTRA Natera, Inc.

已收盘 10-21 16:00:00 EDT

413.38

+7.46

+1.84%

盘后413.38

+0.000.00%

19:58 EDT

最高420.15	最低404.84	成交量128.58万
今开404.84	昨收405.92	日振幅3.77%
总市值592.02亿	流通市值574.60亿	总股本1.43亿
成交额5.34亿	换手率0.93%	流通股本1.39亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NTRA","market":"US","secType":"STK","nameCN":"Natera, Inc.","latestPrice":413.38,"timestamp":1792612800000,"preClose":405.92,"halted":0,"volume":1285815,"hourTrading":{"tag":"盘后","latestPrice":413.38,"preClose":413.38,"latestTime":"19:58 EDT","volume":59813,"amount":24726586.1291,"timestamp":1792627084939,"change":0,"changeRate":0,"amplitude":0.002177},"delay":0,"changeRate":0.018378005518328685,"floatShares":139000000,"shares":143215382,"eps":-1.372894,"marketStatus":"已收盘","change":7.46,"latestTime":"10-21 16:00:00 EDT","open":404.84,"high":420.1499,"low":404.84,"amount":534396646.3632,"amplitude":0.037717,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.372894,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1792656000000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1435809600000,"exchange":"NASDAQ","adjPreClose":405.92,"preHourTrading":{"tag":"盘前","latestPrice":404.5,"preClose":405.92,"latestTime":"09:27 EDT","volume":375,"amount":152427.11250000002,"timestamp":1792589260046,"change":-1.42,"changeRate":-0.003498,"amplitude":0.021655},"postHourTrading":{"tag":"盘后","latestPrice":413.38,"preClose":413.38,"latestTime":"19:58 EDT","volume":59813,"amount":24726586.1291,"timestamp":1792627084939,"change":0,"changeRate":0,"amplitude":0.002177},"volumeRatio":1.045924,"impliedVol":0.6335,"impliedVolPercentile":0.8287},"requestUrl":"/m/hq/s/NTRA","defaultTab":"news","newsList":[{"id":"1134003322","title":"异动解读｜Natera盘中上涨3.13%，目标价上调叠加产品进展强化估值预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1134003322","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134003322?lang=zh_cn&edition=full","pubTime":"2026-10-21 21:53","pubTimestamp":1792590783,"startTime":"0","endTime":"0","summary":"10月21日，Natera盘中上涨3.13%，报418.615美元/股，成交额5222.68万美元。本次异动的直接催化，来自投行近期上调目标价并维持增持立场，叠加公司在多癌早筛与Signatera商业化上的连续进展，带动资金回流基因检测主线。此前摩根士丹利将其目标价由355美元上调至435美元；公司多癌早筛检测亦获FDA突破性设备认定，Signatera已在日本获批用于肌层浸润性膀胱癌伴随诊断。基本面方面，公司二季度营收7.53亿美元，同比增长37.7%，并将全年营收指引上调至28.5亿至29.1亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Natera获大行上调目标价，股价盘中上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174400496","title":"异动解读｜Natera盘中上涨3.03%，投行上调目标价后资金重回基因检测主线","url":"https://stock-news.laohu8.com/highlight/detail?id=1174400496","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174400496?lang=zh_cn&edition=full","pubTime":"2026-10-19 23:14","pubTimestamp":1792422849,"startTime":"0","endTime":"0","summary":"10月19日，Natera盘中上涨3.03%，报405.36美元/股，成交额1.17亿美元。消息面上，摩根士丹利近日将公司目标价由355美元上调至435美元，并维持增持评级，继续强化市场对其估值上修预期。同时，公司多癌早筛检测获FDA突破性设备认定，Signatera已在日本获批用于肌层浸润性膀胱癌伴随诊断，皮肤癌和乳腺癌相关临床项目也在推进。此前公司二季度营收7.53亿美元，同比增长37.7%，并上调全年营收指引至28.5亿至29.1亿美元。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"股价上涨，基因检测龙头获投行力挺","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146436479","title":"异动解读｜Natera盘中下跌3.09%，投行上调目标价后短线回吐压力再现","url":"https://stock-news.laohu8.com/highlight/detail?id=1146436479","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146436479?lang=zh_cn&edition=full","pubTime":"2026-10-16 22:01","pubTimestamp":1792159268,"startTime":"0","endTime":"0","summary":"10月16日，Natera盘中下跌3.09%，报392.58美元/股，成交额4288.08万美元。消息面上，摩根士丹利近日将公司目标价由355美元上调至435美元并维持增持评级，但股价在前期强势后再度出现获利回吐。与此同时，公司多癌早筛检测获FDA突破性设备认定，Signatera已在日本获批用于肌层浸润性膀胱癌伴随诊断，皮肤癌和乳腺癌相关临床项目也在推进。不过生物科技板块承压，Moderna盘中跌超10%，短线情绪压制利好兑现。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Natera短线回吐，利好催化仍受关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168638777","title":"异动解读｜Natera盘中上涨3.15%，投行上调目标价后资金重回基因检测主线","url":"https://stock-news.laohu8.com/highlight/detail?id=1168638777","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168638777?lang=zh_cn&edition=full","pubTime":"2026-10-16 03:09","pubTimestamp":1792091347,"startTime":"0","endTime":"0","summary":"10月16日，Natera盘中上涨3.15%，报407.2美元/股，成交额3.19亿美元。消息面上，摩根士丹利近日将Natera目标价由355美元上调至435美元，并维持增持评级，叠加公司多癌早筛检测获FDA突破性设备认定，带动市场继续关注其长期增长前景。此外，Signatera此前已在日本获批用于肌层浸润性膀胱癌伴随诊断，公司近期还推进皮肤癌和乳腺癌相关临床项目。8月公司披露二季度营收7.53亿美元，同比增37.7%，并上调全年营收指引至28.5亿至29.1亿美元。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Natera获大行上调目标价，股价上涨引资金回流","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106930041","title":"异动解读｜Natera盘中下跌3.24%，投行上调目标价不改获利回吐压力","url":"https://stock-news.laohu8.com/highlight/detail?id=1106930041","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106930041?lang=zh_cn&edition=full","pubTime":"2026-10-13 21:52","pubTimestamp":1791899579,"startTime":"0","endTime":"0","summary":"10月13日，Natera盘中下跌3.24%，报384.89美元/股，成交额3740.92万美元。消息面上，摩根士丹利近日将Natera目标价从355美元上调至435美元，并维持增持评级，但股价在前期连续走强后仍出现回吐。公司近期基本面催化持续，包括多癌早筛检测获得FDA突破性设备认定、Signatera在日本获批用于膀胱癌伴随诊断，且皮肤癌、乳腺癌等临床项目推进中。不过当前生物科技板块整体偏弱，Moderna同步下跌，短线情绪压制强于利好兑现。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Natera股价回落，大摩上调目标价","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190330401","title":"异动解读｜Natera盘中下跌3.18%，投行上调目标价不改获利回吐压力","url":"https://stock-news.laohu8.com/highlight/detail?id=1190330401","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190330401?lang=zh_cn&edition=full","pubTime":"2026-10-13 00:57","pubTimestamp":1791824236,"startTime":"0","endTime":"0","summary":"10月13日，Natera盘中下跌3.18%，报387.98美元/股，成交额1.46亿美元。消息面上，摩根士丹利将Natera目标价从355美元上调至435美元并维持增持评级，但股价在近期连续上涨后出现获利回吐。近期Natera在多癌早期检测领域取得进展，其多癌筛查检测获FDA突破性设备认定，Signatera测试也在日本获批用于膀胱癌伴随诊断，公司临床管线持续扩张。尽管投行目标价上调反映对长期基本面的看好，但短期内市场情绪受生物科技板块整体走弱影响，Moderna下跌4.58%，行业回调压力明显。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Natera盘中走低，投行却上调目标价","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141890516","title":"异动解读｜Natera盘中上涨3.05%，多癌早筛获FDA突破性器械认定","url":"https://stock-news.laohu8.com/highlight/detail?id=1141890516","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141890516?lang=zh_cn&edition=full","pubTime":"2026-10-09 21:42","pubTimestamp":1791553348,"startTime":"0","endTime":"0","summary":"10月9日，Natera盘中上涨3.05%，报402.71美元/股，成交额1969.63万美元。消息面上，公司多癌早期检测试剂盒获得美国FDA突破性器械认定，叠加此前乳腺癌三期临床启动的积极进展，推动股价在近期获利回吐后重拾升势。该多癌早筛检测通过分析血液中的游离DNA实现对多种癌症的筛查，突破性器械认定旨在加快产品开发、评估、审评及上市授权流程。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Natera获FDA突破性认定，多癌早筛提振股价","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178233951","title":"异动解读｜Natera盘中下跌3.33%，黑色素瘤临床启动后获利回吐延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1178233951","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178233951?lang=zh_cn&edition=full","pubTime":"2026-10-08 22:07","pubTimestamp":1791468428,"startTime":"0","endTime":"0","summary":"10月8日，Natera盘中下跌3.33%，报382.25美元/股，成交额1.14亿美元。消息面上，公司在宣布与NYU Langone Health合作启动针对晚期黑色素瘤的Signatera临床研究后，股价延续近期获利回吐压力。此前因乳腺癌三期临床启动带来的涨幅已连续多日出现资金了结迹象。最新试验将利用Signatera在影像学进展前检测持续性分子残留病灶，以指导晚期或转移性黑色素瘤患者的治疗升级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Natera盘中下跌，黑色素瘤试验启动后获利回吐","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189083692","title":"异动解读｜Natera盘中下跌3.73%，乳腺癌三期临床后获利回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1189083692","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189083692?lang=zh_cn&edition=full","pubTime":"2026-10-07 21:46","pubTimestamp":1791380794,"startTime":"0","endTime":"0","summary":"10月7日，Natera盘中下跌3.73%，报390.535美元/股，成交额3.38亿美元。消息面上，公司在宣布启动针对晚期黑色素瘤的Signatera临床研究后，股价并未获得持续提振，而此前因乳腺癌三期临床启动带来的涨幅出现获利了结压力。最新动态显示，Natera与NYU Langone Health合作启动一项试验，利用Signatera在影像学进展前检测持续性分子残留病灶，以指导晚期或转移性黑色素瘤患者的治疗升级。Natera专注于无创cfDNA技术，通过分子分析与生物信息技术实现多种严重疾病的精准检测与健康管理。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Natera盘中走低，乳腺癌临床后回吐","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178450429","title":"异动解读｜Natera盘中下跌3.04%，乳腺癌三期临床启动后股价回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1178450429","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178450429?lang=zh_cn&edition=full","pubTime":"2026-10-06 22:07","pubTimestamp":1791295640,"startTime":"0","endTime":"0","summary":"10月6日，Natera盘中下跌3.04%，报412.7美元/股，成交额1.52亿美元。此前一日公司股价因乳腺癌三期临床启动上涨3.73%，今日出现回吐。尽管临床进展积极，但股价在利好兑现后出现获利了结压力。值得关注的是，多家投行近期密集上调Natera目标价，RBC将其目标价从350美元上调至460美元，UBS从290美元上调至435美元，反映市场对其MRD检测业务的长期信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"乳腺癌三期启动后股价回吐，Natera盘中下跌","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138176230","title":"异动解读｜Natera盘中上涨3.05%，乳腺癌三期临床研究启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1138176230","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138176230?lang=zh_cn&edition=full","pubTime":"2026-10-06 03:13","pubTimestamp":1791227597,"startTime":"0","endTime":"0","summary":"10月6日，Natera盘中上涨3.05%，报422.88美元/股，成交额5.6亿美元。消息面上，公司与Alliance Foundation Trials联合启动了一项涉及2000名患者的ER阳性/HER2阴性乳腺癌三期临床试验。该研究将结合罗氏旗下Genentech研发的口服雌激素受体降解剂giredestrant，通过Signatera基因监测技术指导CDK4/6抑制剂治疗升级。这是继今年6月Signatera在日本获批结直肠癌伴随诊断后，公司在实体瘤领域的又一重要布局。Natera专注于利用无创cfDNA技术实现精准健康管理，其分子分析方法可高精度识别多种严重疾病变异。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119549804","title":"异动解读｜Natera盘中上涨3.05%，RBC大幅上调目标价至460美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119549804","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119549804?lang=zh_cn&edition=full","pubTime":"2026-09-30 23:29","pubTimestamp":1790782155,"startTime":"0","endTime":"0","summary":"9月30日，Natera盘中上涨3.05%，报427.18美元/股，成交额1.95亿美元。消息面上，RBC Capital Markets近日将Natera目标价从350美元大幅上调至460美元，维持\"跑赢大盘\"评级，并指出其新一代超高灵敏度分子残留病灶检测产品Signatera Genome有望在未来几年内成为该领域的主导临床产品。此外，Natera近期获得日本PMDA批准Signatera作为肌层浸润性膀胱癌伴随诊断工具，预计明年上半年在日本商业化推出。UBS此前也将目标价从290美元上调至435美元，维持买入评级，多家机构持续看多。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Natera获大行力挺，股价强势上扬","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148414595","title":"异动解读｜Natera盘中上涨3.22%，Signatera获日本膀胱癌伴随诊断批准叠加多家投行上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1148414595","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148414595?lang=zh_cn&edition=full","pubTime":"2026-09-24 21:59","pubTimestamp":1790258348,"startTime":"0","endTime":"0","summary":"9月24日，Natera盘中上涨3.22%，报403.35美元/股，成交额6627.14万美元。消息面上，日本药品与医疗器械管理局近日批准Natera旗下Signatera检测产品作为肌层浸润性膀胱癌的伴随诊断工具，用于指导阿替利珠单抗辅助治疗决策，该批准基于III期IMvigor011临床试验数据，公司预计明年上半年在日本商业化推出该检测。这是Signatera继今年6月获日本结直肠癌MRD检测批准后在日本拿下的第二项适应症，持续拓宽国际商业化版图。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Natera获日本膀胱癌伴随诊断批准，机构集体上调目标价","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161560231","title":"异动解读｜Natera盘中上涨3.1%，Signatera获日本批准用于膀胱癌伴随诊断","url":"https://stock-news.laohu8.com/highlight/detail?id=1161560231","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161560231?lang=zh_cn&edition=full","pubTime":"2026-09-22 22:12","pubTimestamp":1790086372,"startTime":"0","endTime":"0","summary":"9月22日，Natera盘中上涨3.1%，报382.13美元/股，成交额5736.57万美元。消息面上，日本药品与医疗器械管理局批准Natera旗下Signatera检测产品作为肌层浸润性膀胱癌的伴随诊断工具，用于指导阿替利珠单抗辅助治疗决策。这是Signatera继今年6月获日本结直肠癌MRD检测批准后，在日本市场拿下的第二项适应症，持续拓宽其国际商业化版图。此外，近期多家投行上调Natera目标价，UBS将目标价由290美元上调至435美元，Rothschild以385美元目标价首次覆盖，均维持买入评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Natera上涨，Signatera获日本膀胱癌伴随诊断批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136180716","title":"Signatera™在日本获批为肌层浸润性膀胱癌伴随诊断工具","url":"https://stock-news.laohu8.com/highlight/detail?id=1136180716","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136180716?lang=zh_cn&edition=full","pubTime":"2026-09-22 20:01","pubTimestamp":1790078476,"startTime":"0","endTime":"0","summary":"Signatera™在日本获得监管批准，正式成为肌层浸润性膀胱癌领域的伴随诊断产品。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0963586101.USD","LU2065731478.USD","LU2065171311.SGD","LU2264538146.SGD","NTRA","LU2065170008.USD","LU2065171402.SGD","HELX","LU0345770993.USD","LU2324357040.USD","LU1064131342.USD","GNOM","LU0012050646.USD","BK4139","LU0106261612.USD","LU1988902786.USD","LU0053671581.USD","LU0345770308.USD","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126381549","title":"异动解读｜Natera盘中上涨3.18%，多家投行大幅上调目标价提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1126381549","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126381549?lang=zh_cn&edition=full","pubTime":"2026-09-17 22:00","pubTimestamp":1789653622,"startTime":"0","endTime":"0","summary":"9月17日，Natera盘中上涨3.18%，报355.63美元/股，成交额3372.61万美元。消息面上，近期多家投行密集上调Natera评级及目标价。UBS将目标价由290美元大幅上调至435美元，维持买入评级；Rothschild & Co Redburn以385美元目标价首次覆盖并给予买入评级。此外，Signatera检测产品接连获得FDA伴随诊断批准、日本PMDA监管许可及EU IVDR认证，商业化进程加速，为股价上行提供支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Natera获多家投行上调目标价，股价应声上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165686021","title":"Natera携手Susan G. Komen® 共推乳腺癌防治新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=1165686021","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165686021?lang=zh_cn&edition=full","pubTime":"2026-08-28 23:07","pubTimestamp":1787929655,"startTime":"0","endTime":"0","summary":"Natera与Susan G. Komen®共同宣布，双方将建立全国性合作伙伴关系，旨在加速推动乳腺癌防治领域的进展。这一战略联盟汇聚了精准医疗领域的先锋力量与全球知名的乳腺癌公益组织，有望为患者带来更为精准、高效的诊疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","LU2065171402.SGD","LU0963586101.USD","LU0106261612.USD","LU1064131342.USD","LU1988902786.USD","LU0345770993.USD","LU2065171311.SGD","BK4139","LU2065169927.USD","LU0053671581.USD","LU0345770308.USD","GNOM","LU2264538146.SGD","NTRA","LU2324357040.USD","HELX","LU0012050646.USD","LU2065731478.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172077351","title":"Natera助力新临床研究：利用Latitude™评估晚期皮肤癌ctDNA动态变化","url":"https://stock-news.laohu8.com/highlight/detail?id=1172077351","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172077351?lang=zh_cn&edition=full","pubTime":"2026-08-12 18:02","pubTimestamp":1786528935,"startTime":"0","endTime":"0","summary":"Natera将支持一项全新临床试验，旨在评估Latitude™技术在晚期皮肤癌中监测循环肿瘤DNA（ctDNA）动态变化的能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELX","GNOM","LU2264538146.SGD","LU0345770308.USD","LU1988902786.USD","LU0106261612.USD","LU0053671581.USD","NTRA","LU2065170008.USD","LU0963586101.USD","LU2065171311.SGD","LU2065171402.SGD","LU0345770993.USD","LU0012050646.USD","LU1064131342.USD","LU2065731478.USD","BK4139","LU2324357040.USD","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148194782","title":"异动解读｜Natera盘中上涨19.24%，Q2营收大超预期叠加全年指引上调","url":"https://stock-news.laohu8.com/highlight/detail?id=1148194782","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148194782?lang=zh_cn&edition=full","pubTime":"2026-08-07 21:42","pubTimestamp":1786110134,"startTime":"0","endTime":"0","summary":"8月7日，Natera盘中上涨19.24%，报316.0美元/股，成交额1.11亿美元。消息面上，公司发布Q2财报，营收7.528亿美元，同比增长37.7%，大幅超出市场一致预期的6.61亿美元；调整后每股亏损0.47美元，优于预期的0.49美元。同时，公司将全年营收指引上调至28.5亿至29.1亿美元，高于此前的27.4亿至28.2亿美元及市场预期的28.0亿美元。此外，RBC Capital将目标价从275美元上调至350美元，维持\"跑赢大盘\"评级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Natera盘中上涨19.24%，Q2营收大超预期叠加全年指引上调","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122596166","title":"异动解读｜Natera盘前上涨13.42%，Q2营收大超预期叠加全年指引上调","url":"https://stock-news.laohu8.com/highlight/detail?id=1122596166","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122596166?lang=zh_cn&edition=full","pubTime":"2026-08-07 19:15","pubTimestamp":1786101307,"startTime":"0","endTime":"0","summary":"8月7日，Natera盘前上涨13.42%，报300.94美元/股。消息面上，公司盘后发布Q2财报，营收7.528亿美元，同比增长37.7%，大幅超出市场一致预期的6.61亿美元；调整后每股亏损0.47美元，优于预期的0.49美元，同比改善36.5%。同时，公司将全年营收指引上调至28.5亿至29.1亿美元，高于此前的27.4亿至28.2亿美元及市场预期的28.0亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Natera盘前上涨13.42%，Q2营收大超预期叠加全年指引上调","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.natera.com","stockEarnings":[{"period":"1week","weight":0.0259},{"period":"1month","weight":0.0989},{"period":"3month","weight":0.5363},{"period":"6month","weight":1.0181},{"period":"1year","weight":1.1523},{"period":"ytd","weight":0.7719}],"compareEarnings":[{"period":"1week","weight":-0.0115},{"period":"1month","weight":0.0097},{"period":"3month","weight":0.029},{"period":"6month","weight":0.0855},{"period":"1year","weight":0.1456},{"period":"ytd","weight":0.1278}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Natera, Inc.于2007年1月在特拉华州成立。该公司是一家诊断公司，拥有专有的分子和生物信息技术，该公司正在应用该技术来改变全球范围内的疾病管理。该公司的无细胞DNA（CFDNA）技术结合了新颖的分子分析方法，这些方法可以从小到单个细胞的样本中可靠地测量整个基因组中的许多信息区域，以及统计算法，这些算法结合了更广泛的科学界提供的数据，以高精度和高覆盖率识别涵盖广泛严重疾病的遗传变异。该公司的目标是使个性化基因检测和诊断成为保护健康的护理标准的一部分，并告知更早和更有针对性的干预措施，以帮助实现更长寿、更健康的生活。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":-0.017867},{"month":2,"riseRate":0.545455,"avgChangeRate":0.019142},{"month":3,"riseRate":0.454545,"avgChangeRate":0.002026},{"month":4,"riseRate":0.727273,"avgChangeRate":0.035796},{"month":5,"riseRate":0.818182,"avgChangeRate":0.097296},{"month":6,"riseRate":0.818182,"avgChangeRate":0.127144},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.000068},{"month":8,"riseRate":0.833333,"avgChangeRate":0.157241},{"month":9,"riseRate":0.416667,"avgChangeRate":-0.021704},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.036544},{"month":11,"riseRate":0.545455,"avgChangeRate":0.100491},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.000753}],"exchange":"NASDAQ","name":"Natera, Inc.","nameEN":"Natera"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Natera, Inc.(NTRA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Natera, Inc.(NTRA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Natera, Inc.,NTRA,Natera, Inc.股票,Natera, Inc.股票老虎,Natera, Inc.股票老虎国际,Natera, Inc.行情,Natera, Inc.股票行情,Natera, Inc.股价,Natera, Inc.股市,Natera, Inc.股票价格,Natera, Inc.股票交易,Natera, Inc.股票购买,Natera, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Natera, Inc.(NTRA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Natera, Inc.(NTRA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}